Quellenverzeichnis

Alle Quellen der Gesamtstudie (123 Einträge), geordnet nach Kennung. Titel in der Originalsprache; bei nicht englischen oder deutschen Titeln steht die deutsche Übersetzung in Klammern. Wo keine PMID oder DOI vorhanden ist, steht die Internetadresse des abgerufenen Dokuments.

• [s01] Albokhadaim I (2026): Tirzepatide ameliorates type 2 diabetes-associated male reproductive dysfunction via modulation of the Nrf2/Keap1 pathway. Toxicology research. PMID 41756101; DOI 10.1093/toxres/tfag010
• [s02] Becker AS, Castilhos JP, Shugair SAS et al. (2026): GLP-1 Receptor Agonists and Fertility: What Is Known So Far? JBRA assisted reproduction. PMID 42441883; DOI 10.5935/1518-0557.20260028
• [s03] Broul M, Dubský M, Hujová A et al. (2026): Male Sexual and Reproductive Health in Diabetes and Obesity Pharmacotherapy: A Source-Triangulated Counseling Map. Andrology. PMID 42661473; DOI 10.1111/andr.70366
• [s04] Dasso ME, Centola CL, Sobarzo CM et al. (2026): Glucagon-like peptide-1 analog, liraglutide, alters blood-testis barrier permeability in juvenile healthy rats. Environmental toxicology and pharmacology. PMID 41856344; DOI 10.1016/j.etap.2026.104998
• [s05] Deameh MG, Ramez M, Rowaiee R et al. (2026): Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. The journal of sexual medicine. PMID 41498523; DOI 10.1093/jsxmed/qdaf381
• [s06] EAU Guidelines Office (2026): EAU Guidelines on Sexual and Reproductive Health, Kapitel Male Infertility. European Association of Urology. https://uroweb.org/guidelines/sexual-and-reproductive-health/chapter/male-infertility
• [s07] EAU Guidelines Office (2026): EAU Guidelines on Sexual and Reproductive Health, Kapitel Male Hypogonadism. European Association of Urology. https://uroweb.org/guidelines/sexual-and-reproductive-health/chapter/male-hypogonadism
• [s08] ESHRE (2026): ESHRE Guidelines, Consensus Documents and Recommendations (Übersichtsseite) European Society of Human Reproduction and Embryology. https://www.eshre.eu/Guidelines-and-Legal/Guidelines
• [s09] Fernandes BFO (2026): Agonistas do recetor do péptido semelhante ao glucagon tipo 1 e fertilidade masculina (Agonisten des GLP-1-Rezeptors und männliche Fertilität) Masterarbeit, Universidade do Porto (Repositório Aberto). https://hdl.handle.net/10216/174947
• [s10] Fuentes-Mendoza JM, Concepción-Zavaleta MJ, Mendoza-Godoy JJ et al. (2026): Beyond metabolism: sexual dysfunction and weight-loss drugs. Sexual medicine reviews. PMID 41427954; DOI 10.1093/sxmrev/qeaf074
• [s11] Gelfand ST, Tveit MC, Simon JA (2026): Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. Obesity pillars. PMID 41404471; DOI 10.1016/j.obpill.2025.100233
• [s12] Guo Y, Su J, Shen L et al. (2026): Semaglutide treatment in MOSH is associated with altered DNA methylation patterns of genes related to glycolipid metabolism. Scientific reports. PMID 42336886; DOI 10.1038/s41598-026-50299-3
• [s13] Kaltsas A, Gkioxaris V, Giannakas T et al. (2026): GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework. Journal of clinical medicine. PMID 42796084; DOI 10.3390/jcm15187313
• [s14] Khalil W, Bibi K, Fareed T et al. (2026): Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review. Cureus. PMID 42465136; DOI 10.7759/cureus.110952
• [s15] Klotz T (2026): [GLP-1 Receptor Agonists in Urology and Andrology: Indications, Opportunities and Clinically Relevant Adverse Effects]. Zentralblatt fur Chirurgie. PMID 42748969; DOI 10.1055/a-2943-1080
• [s16] Koufakis T, Tsimihodimos V, Popovic DS (2026): Half the genome, half the story? Paternal metabolic health and offspring outcomes in the era of modern obesity pharmacotherapy. Diabetes & metabolism. PMID 41748068; DOI 10.1016/j.diabet.2026.101743
• [s17] Kuchakulla M, Poppas PJ, Wald G et al. (2026): Impact of GLP-1 Receptor Agonists on Male Fertility: Emerging Evidence and Future Directions. Urology. PMID 41016449; DOI 10.1016/j.urology.2025.09.038
• [s18] La Vignera S, Condorelli R (2026): Effects of Incretin-Based Therapies on Testosterone Levels and Incretin Response in Men with Hypogonadism: A Systematic Literature Review Following PRISMA 2020 Guidelines. Pharmaceuticals (Basel, Switzerland). PMID 42653816; DOI 10.3390/ph19081321
• [s19] La Vignera S, Condorelli RA (2026): Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction. Biomedicines. PMID 42512116; DOI 10.3390/biomedicines14071644
• [s20] Lin S, Ding X, Dang X et al. (2026): Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis. Andrology. PMID 41883294; DOI 10.1111/andr.70222
• [s21] Lopez JM (2026): TESTOSTERONA BAJA EN LA ERA GLP-1 (Niedriges Testosteron in der GLP-1-Ära) Zenodo (nicht begutachtet). DOI 10.5281/zenodo.22870442
• [s22] Mendias CL, Awan TM (2026): Improving Erectile Function and Quality of Life in Hypogonadal Euglycemic and Diabetic Men with Refractory Erectile Dysfunction. Preprints.org. DOI 10.20944/preprints202605.1580.v1
• [s23] Merhi Z (2026): GLP-1 receptor agonists and sexual function in women and men: a narrative review of emerging evidence and the need for further research. Sexual medicine reviews. PMID 41870138; DOI 10.1093/sxmrev/qeag015
• [s24] Mirghani HO, AlQurashi AM (2026): Glucagon-like receptor-1 agonists and impotence: A meta-analysis. World journal of methodology. PMID 42626264; DOI 10.5662/wjm.119385
• [s25] Mori Y, Osaka N, Terasaki M et al. (2026): Tirzepatide Attenuates Diabetes-Associated Testicular Inflammation and Sperm DNA Fragmentation in Obese Diabetic Mice: Potential Pleiotropic Effects Beyond Glycemic Control. Research Square. DOI 10.21203/rs.3.rs-10208764/v1
• [s26] Olivares A, Manuel-Apolinar L, de la Chesnaye-Caraveo E et al. (2026): Effects of GLP-1 analogs on metabolic alterations including male sexual function, hypogonadism and erectile dysfunction: a narrative review. Translational andrology and urology. PMID 42582759; DOI 10.21037/tau-2026-0285
• [s27] Paternò V, Abdel Malek R, Delli Paoli E et al. (2026): Beyond metabolic control: the potential role of antidiabetic therapies in modulating male reproductive function and spermatogenesis. Reviews in endocrine & metabolic disorders. PMID 42821207; DOI 10.1007/s11154-026-10090-1
• [s28] Peel A, Lyons H, Tully CA et al. (2026): The effect of obesity interventions on male fertility: a systematic review and meta-analysis. Human reproduction update. PMID 41065428; DOI 10.1093/humupd/dmaf025
• [s29] Portillo-Canales S, Iqbal I, Akande R et al. (2026): Effect of Incretin-Based Weight Loss Drugs on Testosterone Concentrations in Men. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. PMID 41544705; DOI 10.1016/j.eprac.2026.01.003
• [s30] Seminara G, Leuzzi M, Meduri L et al. (2026): Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study. Minerva endocrinology. PMID 41801155; DOI 10.23736/s2724-6507.26.04541-0
• [s31] Sotzen MR, Byun S, Ibadin NO et al. (2026): Beyond weight loss: Disentangling the direct effects of semaglutide vs equivalent calorie restriction on reproductive systems of male and female rats. Molecular metabolism. PMID 42692145; DOI 10.1016/j.molmet.2026.102436
• [s32] Tang H, Lu Y, Zhang B et al. (2026): GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation. EClinicalMedicine. PMID 42005929; DOI 10.1016/j.eclinm.2026.103857
• [s33] Tariq A, Garza Gangemi A, Herrera Caceres J (2026): Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health. Urology case reports. PMID 41716526; DOI 10.1016/j.eucr.2026.103368
• [s34] Wang H, Chang H, Zhao Y et al. (2026): Treatment Options for Improving The Semen Quality in Obese Men: A Scoping Review. Journal of multidisciplinary healthcare. PMID 41883587; DOI 10.2147/jmdh.s582182
• [s35] Xia L, Li F, Yin D et al. (2026): Glucagon receptor blockade protects spermatogenesis by enhancing PFKFB3-mediated lactate production in Sertoli cells. Journal of translational medicine. PMID 42458466; DOI 10.1186/s12967-026-08588-y
• [s36] Yang L, He X, Wang S et al. (2026): Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysis. The journal of sexual medicine. PMID 42704281; DOI 10.1093/jsxmed/qdag272
• [s37] Zafrani Z, Khan SS, Zitzmann M (2026): Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology-A Systematic Review. Cells. PMID 42587729; DOI 10.3390/cells15151319
• [s38] Zeweil MM, Khafaga AF, Shamaa MM et al. (2026): Can Carica papaya Serve as an Adjunct to Semaglutide in Mitigating Diabetes-Induced Testicular Injury Through Modulation of Oxidative Stress, Inflammation, Apoptosis, and the miR-34c/miR-155-SIRT1/FOXO1 Axis? An Experimental and Chem-Bio-Informatics Study. International journal of molecular sciences. PMID 42589610; DOI 10.3390/ijms27156956
• [s39] Тюзиков И.А., Греков Е.А., Смирнов А.В. (Tyuzikov IA, Grekov EA, Smirnov AV) (2026): Репродуктивные эффекты современных гипогликемических препаратов у бесплодных мужчин с сахарным диабетом 2 типа (Reproduktive Effekte moderner blutzuckersenkender Arzneimittel bei unfruchtbaren Männern mit Typ-2-Diabetes) Эффективная фармакотерапия (Effective Pharmacotherapy) 22(31):22-38. DOI 10.33978/2307-3586-2026-22-31-22-38
• [s40] Abdel-Wahab BA, El-Shoura EAM, Habeeb MS et al. (2025): Unraveling the impact of semaglutide in a diabetic rat model of testicular dysfunction: Insights into spermatogenesis pathways and miRNA-148a-5p. Steroids. PMID 39551458; DOI 10.1016/j.steroids.2024.109537
• [s41] Able C, Liao B, Saffati G et al. (2025): Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study. International journal of impotence research. PMID 38778151; DOI 10.1038/s41443-024-00895-6
• [s42] Alafifi SA, Wahdan SA, Elhemiely AA, Elsherbiny DA, Azab SS (2025): Retraction Note: Modulatory effect of liraglutide on doxorubicin-induced testicular toxicity and behavioral abnormalities in rats: role of testicular-brain axis. Naunyn-Schmiedeberg's archives of pharmacology 398(4):4671. PMID 40105924; DOI 10.1007/s00210-025-04046-6
• [s43] An J, Xiang B, Peng J et al. (2025): Understanding the erectile dysfunction-cardiovascular disease connection: clinical and pathophysiological insights. Sex Med Rev. PMID 40153594; DOI 10.1093/sxmrev/qeaf014
• [s44] Antonič KG, Zitzmann M (2025): The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems. The aging male : the official journal of the International Society for the Study of the Aging Male. PMID 41399135; DOI 10.1080/13685538.2025.2601423
• [s45] Bocu K, Boeri L, Mahmutoglu AM, Vogiatzi P (2025): Can lifestyle changes significantly improve male fertility: A narrative review? Arab journal of urology 23(3):190-200. PMID 40747470; DOI 10.1080/20905998.2024.2421626
• [s46] Cowart K, Murphy C, Carris N (2025): Association of tirzepatide with erectile dysfunction in people with type 2 diabetes. Journal of diabetes and its complications. PMID 40614622; DOI 10.1016/j.jdiacomp.2025.109116
• [s47] Ezici A, Ramadan S, Bardak AE et al. (2025): SAT-147 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Erectile Dysfunction and Testosterone Levels: A Systematic Review and Meta-Analysis. Journal of the Endocrine Society (Kongressabstract). DOI 10.1210/jendso/bvaf149.1998
• [s48] Gregorič N, Šikonja J, Janež A et al. (2025): Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. Diabetes, obesity & metabolism. PMID 39511836; DOI 10.1111/dom.16042
• [s49] Harby SA, Fathelbab MH, Nawwar BM et al. (2025): Liraglutide and denatonium benzoate attenuate T2DM-induced metabolic, neurological, and testicular changes in rats: Targeting oxidative stress, inflammation, and BCRP transporter. Journal of molecular histology. PMID 39881033; DOI 10.1007/s10735-025-10355-0
• [s50] Hassan NF, Khidr HY, Eltelbany RFA et al. (2025): Linking GLP-1 activation with steroidogenesis, redox, endoplasmic reticulum stress, mitophagy, and the apoptotic regulatory network unlocks the emerging impacts of semaglutide on 5-fluorouracil-induced testicular toxicity. Life sciences. PMID 41072890; DOI 10.1016/j.lfs.2025.124014
• [s51] Hazir S, Coskun G, Sencar L et al. (2025): Effects of liraglutide on the testis of rats with experimental diabetes and ischemia-reperfusion injury. Biotechnic & histochemistry : official publication of the Biological Stain Commission. PMID 40757489; DOI 10.1080/10520295.2025.2537045
• [s52] Huang R, Xia H, Meng T et al. (2025): Construction of human pluripotent stem cell-derived testicular organoids and their use as humanized testis models for evaluating the effects of semaglutide. Theranostics. PMID 39990223; DOI 10.7150/thno.104523
• [s53] Kounatidis D, Vallianou NG, Rebelos E et al. (2025): The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe? Biomolecules. PMID 41008590; DOI 10.3390/biom15091284
• [s54] La Vignera S, Cannarella R, Garofalo V et al. (2025): Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study. Reproductive biology and endocrinology : RB&E. PMID 40604795; DOI 10.1186/s12958-025-01425-9
• [s55] Lima MBVM, Bandeira JMMD, Freitas GLD et al. (2025): Hipogonadismo hipogonadotrófico associado à obesidade e efeitos do tratamento com liraglutida - relato de caso (Obesitätsassoziierter hypogonadotroper Hypogonadismus und Wirkung der Liraglutid-Behandlung, Fallbericht) Brazilian Journal of Health Review. DOI 10.34119/bjhrv8n2-154
• [s56] Oliveira-Lopes B, Braga PC, Oliveira PF et al. (2025): A Pharmacological Dose of Liraglutide Improves Mitochondrial Performance in Mouse Leydig Cells. International journal of molecular sciences. PMID 41009468; DOI 10.3390/ijms26188903
• [s57] Orra SH, Martinez JVN, Porto BC et al. (2025): Effect of GLP-1 agonists on testosterone levels: a systematic review and meta-analysis. BMC urology. PMID 41291666; DOI 10.1186/s12894-025-02005-0
• [s58] Pereira TA, Thaker N, Rubez AC et al. (2025): Managing obesity-related male infertility: insights from weight loss intervention. Human reproduction (Oxford, England). PMID 41024420; DOI 10.1093/humrep/deaf180
• [s59] Portillo Canales S, Iqbal I, Akande R et al. (2025): MON-708 Effect of Incretin-Based Weight Loss Drugs on Testosterone Concentrations in Men. Journal of the Endocrine Society (Kongressabstract). DOI 10.1210/jendso/bvaf149.1941
• [s60] Pourabhari Langroudi A, Chen AL, Basran S et al. (2025): Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data. International journal of impotence research. PMID 40240532; DOI 10.1038/s41443-025-01061-2
• [s61] Rocco L, Saleh R, Mahmutoglu AM, Shah R, Agarwal A (2025): Obesity and male infertility - a tenuous relationship: Facts discerned for the busy clinicians. Arab journal of urology 23(3):169-176. PMID 40747472; DOI 10.1080/20905998.2025.2473219
• [s62] Salvio G, Ciarloni A, Ambo N et al. (2025): Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta-analysis. Andrology. PMID 40105090; DOI 10.1111/andr.70022
• [s63] Yang B, Cheng H, Hu Y et al. (2025): Effects of Anti-Diabetic Drugs on Erectile Dysfunction: A Systematic Review and Meta-Analysis. Diabetes, metabolic syndrome and obesity : targets and therapy. PMID 39990178; DOI 10.2147/dmso.s503216
• [s64] Yin D, Li F, Xia L et al. (2025): GLP-1 receptor agonists show no detrimental effect on sperm quality in mouse models and cell lines. Endocrine. PMID 40347306; DOI 10.1007/s12020-025-04245-4
• [s65] Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Трошина Е.А., Мазурина Н.В. и др. (Dedov II, Mokrysheva NG, Melnichenko GA, Troshina EA, Mazurina NV et al.) (2025): Клинические рекомендации «Ожирение» Минздрава России. Версия 2024 года (Klinische Leitlinie Adipositas des russischen Gesundheitsministeriums, Fassung 2024) Вестник репродуктивного здоровья (Bulletin of Reproductive Health), Jahrgang laut CyberLeninka-Eintrag 2025. https://cyberleninka.ru/article/n/klinicheskie-rekomendatsii-ozhirenie-minzdrava-rossii-versiya-2024-goda
• [s66] An H, Xie K, Gan H (2024): Glucagon-like peptide-1 receptor agonists and the risk of erectile dysfunction: a drug target Mendelian randomization study. Frontiers in endocrinology. PMID 39605940; DOI 10.3389/fendo.2024.1448394
• [s67] Attia SM, Alshamrani AA, Ahmad SF et al. (2024): Dulaglutide rescues the elevated testicular dysfunction in a mouse model of high-fat diet-induced obesity. Mutation research. Genetic toxicology and environmental mutagenesis. PMID 39147447; DOI 10.1016/j.mrgentox.2024.503805
• [s68] Brannigan RE, Hermanson L, Kaczmarek J et al. (2024): Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (veröffentlicht 2020, geändert 2024) American Urological Association / American Society for Reproductive Medicine. https://www.auanet.org/guidelines-and-quality/guidelines/male-infertility
• [s69] Dasso ME, Centola CL, Galardo MN et al. (2024): Glucagon-like peptide-1 analog, liraglutide, regulates Sertoli cell energy metabolism. The Journal of endocrinology. PMID 39303739; DOI 10.1530/joe-24-0274
• [s70] Du Plessis SS, Omolaoye TS, Cardona Maya WD (2024): Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution. Frontiers in physiology. PMID 39624455; DOI 10.3389/fphys.2024.1496416
• [s71] Iida M, Asano A (2024): Effects of glucagon-like peptide-1 receptor agonists on spermatogenesis-related gene expression in mouse testis and testis-derived cell lines. The Journal of veterinary medical science. PMID 38556323; DOI 10.1292/jvms.24-0042
• [s72] Lengsfeld S, Probst L, Emara Y et al. (2024): Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. EBioMedicine. PMID 39232425; DOI 10.1016/j.ebiom.2024.105284
• [s73] Lisco G, Bartolomeo N, De Tullio A et al. (2024): Long-acting glucagon-like peptide 1 receptor agonists boost erectile function in men with type 2 diabetes mellitus complaining of erectile dysfunction: A retrospective cohort study. Andrology. PMID 37615353; DOI 10.1111/andr.13519
• [s74] Pavli P, Triantafyllidou O, Kapantais E et al. (2024): Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature. International journal of molecular sciences. PMID 38339186; DOI 10.3390/ijms25031909
• [s75] Qi R, Liang Y, Yu J et al. (2024): Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway. Reproductive biology and endocrinology : RB&E. PMID 38509558; DOI 10.1186/s12958-024-01202-0
• [s76] Wang Z, Zhu Z, Liu L et al. (2024): The GLP-1R Agonist Exenatide Improves Sheep Sperm Motility by Regulating Cellular Metabolic Levels. Research Square. DOI 10.21203/rs.3.rs-4747909/v1
• [s77] Zhou L, Dong M, Feng G et al. (2024): Semaglutide mitigates testicular damage in diabetes by inhibiting ferroptosis. Biochemical and biophysical research communications. PMID 38678781; DOI 10.1016/j.bbrc.2024.149996
• [s78] Барсуков И.А., Тазина Т.В., Фаниев М.В. (Barsukov IA, Tazina TV, Faniev MV) (2024): Многогранность репродуктивных нарушений у пациентов с ожирением: взгляд эндокринолога, акушера-гинеколога и уролога (Vielgestaltigkeit reproduktiver Störungen bei Adipositas: Sicht von Endokrinologe, Gynäkologe und Urologe) РМЖ. Мать и дитя (Russian Journal of Woman and Child Health) 7(3):248-258. DOI 10.32364/2618-8430-2024-7-3-10
• [s79] Братчиков О.И., Тюзиков И.А., Греков Е.А., Смирнов А.В. (Bratchikov OI, Tyuzikov IA, Grekov EA, Smirnov AV) (2024): Альтернативные негормональные методы восстановления тестостерона при мужском гипогонадизме с позиций доказательной медицины (обзор литературы) (Alternative nichthormonelle Methoden zur Wiederherstellung des Testosterons bei männlichem Hypogonadismus aus Sicht der evidenzbasierten Medizin, Literaturübersicht) Андрология и генитальная хирургия (Andrology and Genital Surgery) 25(4):15-26. DOI 10.62968/2070-9781-2024-25-4-15-26
• [s80] Мерзлова П.Я., Булгакова С.В., Курмаев Д.П., Шаронова Л.А., Долгих Ю.А., Тренева Е.В., Косарева О.В. (Merzlova PYa et al.) (2024): Мужской гипогонадизм, ассоциированный с ожирением (Mit Adipositas assoziierter männlicher Hypogonadismus) Экспериментальная и клиническая гастроэнтерология (Experimental and Clinical Gastroenterology) (8):65-75. DOI 10.31146/1682-8658-ecg-228-8-65-75
• [s81] Чернова М.О., Роживанов Р.В., Роживанова Е.Р., Есауленко Д.И. (Chernova MO, Rozhivanov RV, Rozhivanova ER, Yesaulenko DI) (2024): Оценка влияния коррекции углеводного обмена и массы тела на эндогенную продукцию тестостерона у мужчин с сахарным диабетом 2 типа, ожирением и синдромом гипогонадизма (Bewertung des Einflusses der Korrektur von Kohlenhydratstoffwechsel und Körpergewicht auf die endogene Testosteronproduktion bei Männern mit Typ-2-Diabetes, Adipositas und Hypogonadismus) Вестник репродуктивного здоровья (Bulletin of Reproductive Health) 3(2):33-40. DOI 10.14341/brh12711
• [s82] Abdel-Hakeem EA, Zenhom NM, Mokhemer SA (2023): Testicular cytoprotective effect of glucagon like peptide-1 in diabetic rats involves inhibition of apoptosis, endoplasmic reticulum stress and activation of autophagy. General physiology and biophysics. PMID 36896943; DOI 10.4149/gpb_2022064
• [s83] Alafifi SA, Wahdan SA, Elhemiely AA et al. (2023): Modulatory effect of liraglutide on doxorubicin-induced testicular toxicity and behavioral abnormalities in rats: role of testicular-brain axis. Naunyn-Schmiedeberg's archives of pharmacology. PMID 37162541; DOI 10.1007/s00210-023-02504-7
• [s84] Castiglione R, Vivacqua A, Santoro M et al. (2023): Glucagon-like Peptide-1 Acts as Signaling Mediator to Modulate Human Sperm Performance via Targeting Akt, JNK and IRS-1 Cell Signaling Cascades: Novel Insights into Sperm Physiopathology. Journal of clinical medicine. PMID 37298039; DOI 10.3390/jcm12113844
• [s85] Chen Y, Shu A, Jiang M et al. (2023): Exenatide improves hypogonadism and attenuates inflammation in diabetic mice by modulating gut microbiota. International immunopharmacology. PMID 37210914; DOI 10.1016/j.intimp.2023.110339
• [s86] Culha MG, Gönültaş S, Tavukçu HH, Bastug Y, Tuken M, Semerciöz A, Sulejman S, Serefoglu EC (2023): The impact of liraglutide treatment on erectile function of the diabetic rats. The European Research Journal (TR-Dizin-Eintrag 1183777). DOI 10.18621/eurj.1140921
• [s87] Fathy MA, Alsemeh AE, Habib MA et al. (2023): Liraglutide ameliorates diabetic-induced testicular dysfunction in male rats: role of GLP-1/Kiss1/GnRH and TGF-β/Smad signaling pathways. Frontiers in pharmacology. PMID 37497106; DOI 10.3389/fphar.2023.1224985
• [s88] La Vignera S, Condorelli RA, Calogero AE et al. (2023): Sexual and Reproductive Outcomes in Obese Fertile Men with Functional Hypogonadism after Treatment with Liraglutide: Preliminary Results. Journal of clinical medicine. PMID 36675601; DOI 10.3390/jcm12020672
• [s89] La Vignera S, Condorelli RA, Calogero AE et al. (2023): OR25-02 Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins. Journal of the Endocrine Society (Kongressabstract). DOI 10.1210/jendso/bvad114.1701
• [s90] Li X, Chen L, Wang Y et al. (2023): Glucagon-like peptide-1 promotes Leydig cell regeneration from stem cells in rats. Reproduction. PMID 36194433; DOI 10.1530/REP-22-0136
• [s91] Rabijewski M (2023): Male-specific consequences of obesity - functional hypogonadism and fertility disorders. Endokrynologia Polska. PMID 37779374; DOI 10.5603/ep.95626
• [s92] Service CA, Puri D, Al Azzawi S et al. (2023): The impact of obesity and metabolic health on male fertility: a systematic review. Fertility and sterility. PMID 37839720; DOI 10.1016/j.fertnstert.2023.10.017
• [s93] Varnum AA, Pozzi E, Deebel NA et al. (2023): Impact of GLP-1 Agonists on Male Reproductive Health-A Narrative Review. Medicina (Kaunas, Lithuania). PMID 38256311; DOI 10.3390/medicina60010050
• [s94] Yazıcı D, Yapıcı Eser H, Kıyıcı S, Sancak S, Sezer H, Uygur M, Yumuk V (2023): Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. Obesity facts 16(2):149-163. PMID 36349778; DOI 10.1159/000526808
• [s95] Abdullah DM, Alsemeh AE, Khamis T (2022): Semaglutide early intervention attenuated testicular dysfunction by targeting the GLP-1-PPAR-α-Kisspeptin-Steroidogenesis signaling pathway in a testicular ischemia-reperfusion rat model. Peptides. PMID 34920048; DOI 10.1016/j.peptides.2021.170711
• [s96] Andersen E, Juhl CR, Kjøller ET et al. (2022): Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. Human reproduction (Oxford, England). PMID 35580859; DOI 10.1093/humrep/deac096
• [s97] Correia AS, Pereira SC, Morais T et al. (2022): Obesity-Related Genes Expression in Testes and Sperm Parameters Respond to GLP-1 and Caloric Restriction. Biomedicines. PMID 36289871; DOI 10.3390/biomedicines10102609
• [s98] Ribeiro JC, Martins AD, Jarak I et al. (2022): Exenatide and Dapagliflozin Combination Enhances Sertoli Cell Secretion of Key Metabolites for Spermatogenesis. Biomedicines. PMID 35625851; DOI 10.3390/biomedicines10051115
• [s99] Rozhivanov RV, Chernova MO, Ioutsi VA, Mel'nichenko GA, Shestakova MV, Mokrysheva NG (2022): [Features of steroidogenesis in men with hypogonadism and type 2 diabetes] (Besonderheiten der Steroidogenese bei Männern mit Hypogonadismus und Typ-2-Diabetes; russischsprachige Originalarbeit, Titel hier nach der englischen Fassung in Europe PMC) Problemy endokrinologii 68(3):113-120. PMID 35841175; DOI 10.14341/probl13129
• [s100] Antinozzi C, Lista M, Caponecchia L et al. (2021): Exploratory Analysis in the Differences in Blood Serum and Seminal Plasma of Adipose-Tissue Related Peptides in Obese and Non-Obese Men and Their Correlations With Semen Parameters. Frontiers in endocrinology. PMID 34393997; DOI 10.3389/fendo.2021.681939
• [s101] Asano A (Projektleiter) (2021): 肥満・糖尿病モデル動物を用いたインクレチンによる雄性生殖機能の調節に関する研究 [KAKENHI 18K06033] (Studie zur Regulation der männlichen Fortpflanzungsfunktion durch Inkretin an Tiermodellen für Adipositas und Diabetes) KAKEN (Forschungsförderung Japan), Abschlussbericht, Projektlaufzeit 2018-04-01 bis 2021-03-31. https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K06033/
• [s102] Cannarella R, Calogero AE, Condorelli RA et al. (2021): Is there a role for glucagon-like peptide-1 receptor agonists in the treatment of male infertility? Andrology. PMID 33818920; DOI 10.1111/andr.13015
• [s103] Degirmentepe RB, Altunrende F, Bozkurt M et al. (2021): Protective effect of liraglutide on experimental testicular ischaemia reperfusion in rats. Andrologia. PMID 33550644; DOI 10.1111/and.14000
• [s104] Graybill S, Hatfield J, Kravchenko M et al. (2021): Neutral effect of exenatide on serum testosterone in men with type 2 diabetes mellitus: A prospective cohort. Andrology. PMID 33400403; DOI 10.1111/andr.12966
• [s105] Pourheydar M, Hasanzadeh S, Razi M et al. (2021): Effects of liraglutide on sperm characteristics and fertilization potential following experimentally induced diabetes in mice. Veterinary research forum : an international quarterly journal. PMID 33953881; DOI 10.30466/vrf.2019.96822.2315
• [s106] Бобков Д.Н., Роживанов Р.В., Витязева И.И. (Bobkov DN, Rozhivanov RV, Vityazeva II) (2021): Показатели качества эякулята мужчин с астенозооспермией и астенотератозооспермией на фоне лечения ожирения лираглутидом (Parameter der Ejakulatqualität bei Männern mit Asthenozoospermie und Asthenoteratozoospermie unter Adipositastherapie mit Liraglutid) Ожирение и метаболизм (Obesity and Metabolism) 18(3):263-267. DOI 10.14341/omet12734
• [s107] Дедов И.И., Шестакова М.В., Мельниченко Г.А., Мазурина Н.В. и др. (Dedov II, Shestakova MV, Melnichenko GA, Mazurina NV et al.) (2021): Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний» (Interdisziplinäre klinische Leitlinie Behandlung der Adipositas und komorbider Erkrankungen) Ожирение и метаболизм (Obesity and Metabolism) 18(1):5-99. DOI 10.14341/omet12714
• [s108] Caltabiano R, Condorelli D, Panza S et al. (2020): Glucagon-like peptide-1 receptor is expressed in human and rodent testis. Andrology. PMID 33460247; DOI 10.1111/andr.12871
• [s109] Rago V, De Rose D, Santoro M et al. (2020): Human Sperm Express the Receptor for Glucagon-like Peptide-1 (GLP-1), Which Affects Sperm Function and Metabolism. Endocrinology. PMID 32157297; DOI 10.1210/endocr/bqaa031
• [s110] Yuan P, Ma D, Gao X et al. (2020): Liraglutide Ameliorates Erectile Dysfunction via Regulating Oxidative Stress, the RhoA/ROCK Pathway and Autophagy in Diabetes Mellitus. Front Pharmacol. PMID 32903510; DOI 10.3389/fphar.2020.01257
• [s111] Jensterle M, Janez A, Fliers E et al. (2019): The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Human reproduction update. PMID 31260047; DOI 10.1093/humupd/dmz019
• [s112] Jensterle M, Podbregar A, Goricar K et al. (2019): Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocrine connections. PMID 30707677; DOI 10.1530/ec-18-0514
• [s113] Martins AD, Monteiro MP, Silva BM et al. (2019): Metabolic dynamics of human Sertoli cells are differentially modulated by physiological and pharmacological concentrations of GLP-1. Toxicology and applied pharmacology. PMID 30296456; DOI 10.1016/j.taap.2018.10.009
• [s114] Zhu L, Zhou J, Pan Y et al. (2019): Glucagon-like peptide-1 receptor expression and its functions are regulated by androgen. Biomed Pharmacother. PMID 31669915; DOI 10.1016/j.biopha.2019.109555
• [s115] Гамидов С.И., Шатылко Т.В., Гасанов Н.Г. (Gamidov SI, Shatylko TV, Gasanov NG) (2019): Мужское здоровье и ожирение — диагностика и терапевтические подходы (Männergesundheit und Adipositas – Diagnostik und therapeutische Ansätze) Ожирение и метаболизм (Obesity and Metabolism) 16(3):29-36. DOI 10.14341/omet10314
• [s116] Dalaklioglu S, Tasatargil A, Kuscu N, Celik S, Celik-Ozenci C, Ozdem S, Barutcigil A, Kucukcetin I (2018): Protective effect of exendin-4 treatment on erectile dysfunction induced by chronic methylglyoxal administration in rats. Peptides 106:1-8. PMID 29792899; DOI 10.1016/j.peptides.2018.05.005
• [s117] Shao N, Yu XY, Yu YM et al. (2018): Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity. Andrologia. PMID 29740874; DOI 10.1111/and.13039
• [s118] Yesil S, Sungu N, Kilicarslan A, Kuskonmaz SM, Kara H, Kucuk A, et al. (2018): Exenatide reduces oxidative stress and cell death in testis in iron overload rat model. Experimental and therapeutic medicine 16(6):4349-4356. PMID 30546390; DOI 10.3892/etm.2018.6795
• [s119] Shimizu T, Sato T, Tsukiyama K et al. (2017): Food Intake Affects Sperm-Egg Fusion Through the GIP/PSG17 Axis in Mice. Endocrinology. PMID 28430907; DOI 10.1210/en.2016-1861
• [s120] Yue L, Xu JL, Dong J et al. (2016): Regulatory effect of liraglutide on the expression of eNOS in the corpus cavernosum of diabetic rats (englischer Titel laut PubMed; Originaltitel chinesisch; deutsch: Regulierende Wirkung von Liraglutid auf die eNOS-Expression im Corpus cavernosum diabetischer Ratten) Zhonghua Nan Ke Xue. PMID 27172659
• [s121] Giagulli VA, Carbone MD, Ramunni MI et al. (2015): Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology. PMID 26447645; DOI 10.1111/andr.12099
• [s122] Zhang E, Xu F, Liang H et al. (2015): GLP-1 Receptor Agonist Exenatide Attenuates the Detrimental Effects of Obesity on Inflammatory Profile in Testis and Sperm Quality in Mice. American journal of reproductive immunology (New York, N.Y. : 1989). PMID 26287267; DOI 10.1111/aji.12420
• [s123] Fontoura P, Cardoso MC, Erthal-Martins MC et al. (2014): The effects of liraglutide on male fertility: a case report. Reproductive biomedicine online. PMID 25246122; DOI 10.1016/j.rbmo.2014.07.009